COMPANY UPDATES
09
Sep
2019
Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development

Lab-grown heart tissues and chambers from Novoheart, demonstrate advanced capabilities for drug screening as well as disease modeling which can lead to safer drugs with better efficacy, according to new research. Novoheart’s bio-artificial human heart tissues and chambers are used by global pharmaceutical companies for accurate preclinical testing of the effectiveness and safety of new drugs, with a mission of maximizing the successes in drug discovery while minimizing costs and harm caused to patients. Results from two research contracts with Pfizer’s Global Safety Pharmacology Unit and Rare Disease Research Unit show that using cells from either healthy individuals or patients with a rare inherited disease, Novoheart’s proprietary MyHeartTM Platform can achieve key outcomes needed to improve the drug discovery and development pipeline.


For more detailed press release, please click here.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!